Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
1 clinical trials · Condition
◉ Watch Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers (NCT03912831) | Gilead Sciences | 2019-04-30 |
Track Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer automatically
Every clearance here is in the API, with alerts when new ones post.